共 253 条
[1]
Safdar N(2004)In vivo pharmacodynamic activity of daptomycin Antimicrob Agents Chemother 48 63-68
[2]
Andes D(2013)Variability of pharmacokinetic parameters in patients receiving different dosages of daptomycin: is therapeutic drug monitoring necessary? J Infect Chemother 19 732-739
[3]
Craig WA(2015)Evaluation of daptomycin exposure and efficacy and safety endpoints to support risk-versus-benefit considerations Antimicrob Agents Chemother 60 1600-1607
[4]
Falcone M(2011)Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Clin Infect Dis 52 e18-e55
[5]
Russo A(2010) infections in adults and children Clin Infect Dis 50 1568-1574
[6]
Cassetta MI(2004)Daptomycin exposure and the probability of elevations in the creatine phosphokinase level: data from a randomized trial of patients with bacteremia and endocarditis Antimicrob Agents Chemother 48 2799-2807
[7]
Lappa A(2017)Population pharmacokinetics of daptomycin J Antimicrob Chemother 72 2342-2350
[8]
Tritapepe L(2014)Population pharmacokinetics and dosing considerations for the use of daptomycin in adult patients with hematological malignancies J Antimicrob Chemother 69 200-210
[9]
d'Ettorre G(2019)Clinical and pharmacokinetic considerations for the use of daptomycin in patients with J Antimicrob Chemother 74 117-125
[10]
Bhavnani SM(2005) bacteraemia and severe renal impairment J Clin Pharmacol 45 48-56